Skip to content

Study of possible nech metastasis of oral cancer

Lymphatic mapping in oropharyngeal neoplasms: comparison between Dynamic Lymphoscintigrafy and Fluorescence Lymphografy using indocyanine green dye (ICG). Validation study.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-002542-12-IT
Enrollment
Unknown
Registered
2012-08-08
Start date
2012-09-19
Completion date
Unknown
Last updated
2012-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: VERDE INDOC.PULS.*INIET 5FL25M Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: INDOCYANINE GREEN CAS Number: 3599-32-4 Concentration unit: mg/ml milligram(s)/mi

Sponsors

ISTITUTO EUROPEO DI ONCOLOGIA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male e Female of age = 18 years old. Histological confirmed diagnosis of epithelial tumors of the oral cavity. Primary tumor cT4 candidate to major surgery with cervical access. Absence of clinically positive lymph nodes. Absence of previous treatments. Signed Informed Consent. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 4

Exclusion criteria

Exclusion criteria: Hypersensitivity / known allergy to ICG, sodium iodide or iodine; Hyperthyroidism; Thyroid carcinoma; Pregnancy and / or lactation; Taking drugs that affect liver function; Renal failure; Taking medications that can alter the absorption of indocyanine-green; Psychiatric disorders or any disease that compromises the ability to provide informed consent for participation in this study.

Design outcomes

Primary

MeasureTime frame
Main Objective: Validation of the new method, the fluorescence lymphography, by direct comparison with the gold standard method, the radio colloid.;Secondary Objective: na;Primary end point(s): diagnostic sensibility in terms of true and false positive and false negative;Timepoint(s) of evaluation of this end point: At the time of the histopathological evaluation of the lymphonodes obtained during surgery.

Secondary

MeasureTime frame
Secondary end point(s): Positive predictive value (PPV);Timepoint(s) of evaluation of this end point: at the end of the study

Countries

Italy

Contacts

Public ContactUfficio studi clinici

Istituto Europeo Oncologia

ufficio.studiclinici@ieo.it02 57 48 98 48

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026